SEATTLE, Nov. 28 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced that it plans to publicly offer 10,000,000 shares of its common stock pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. The Company also intends to grant the underwriters of the offering an option to purchase up to an additional 1,500,000 shares of common stock. All of the shares will be sold by Dendreon. Banc of America Securities LLC will be the book-running manager for the offering. JMP Securities and Lazard Capital Markets will be co-managers.
A preliminary prospectus supplement relating to the offering of the securities will be filed with the Securities and Exchange Commission but remains subject to completion. These securities may not be sold nor may offers to buy the securities be accepted prior to the time that the prospectus supplement and related prospectus are delivered in final form. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Copies of the preliminary prospectus supplement relating to the offering may be obtained from Banc of America Securities LLC (by email at dg.prospectus_distribution@bofasecurities.com) or from Dendreon Corporation (Attn: Investor Relations, 3005 First Avenue, Seattle, WA 98121).
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the development of innovative cancer treatments. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon’s product pipeline also includes monoclonal antibody and small molecule product candidates. Dendreon also has collaboration agreements relating to the development of potential product candidates with Genentech, Inc., Abgenix, Inc. and Dyax Corp.
Forward Looking Statements
This news release contains forward-looking statements regarding expectations as to the potential consummation of a public offering. A number of risks and uncertainties could cause actual events to differ from Dendreon’s expectations indicated by these forward-looking statements. These risks are addressed in Dendreon’s periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K for the fiscal year ended December 31, 2004, as amended, and its Quarterly Reports on Form 10-Q filed during the fiscal year ending December 31, 2005.
Dendreon Corporation
CONTACT: Monique Greer, Sr. Director, Corporate Communications of DendreonCorporation, +1-206-829-1500
Web site: http://www.dendreon.com/
